Last updated: 11/19/2026 18:00:11

A Study to Evaluate the Effect of Itraconazole on the Concentration of GSK3923868 in the Blood in Healthy Participants

GSK study ID
218376
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Single-Centre, Open-Label, Single Sequence Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Single Inhaled Doses of GSK3923868 in Healthy Participants
Trial description: The purpose of this study is to evaluate how itraconazole affects the blood concentration of GSK3923868 in healthy adults.
Primary purpose:
Treatment
Trial design:
Sequential Assignment
Masking:
None (Open Label)
Allocation:
Not applicable
Primary outcomes:

Treatment Period 1: Area Under Plasma Concentration Versus Time Curve from Time Zero to Last Quantifiable Concentration [AUC(0-t)] for GSK3923868

Timeframe: Pre-dose, 5, 15, 30, 45 minutes (min), and 1, 2, 4, 6, 8, 12, 16, 24, 48 hours (h) post-dose

Treatment Period 2: AUC(0-t) for GSK3923868

Timeframe: Pre-dose, 5, 15, 30, 45 min, and 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96, 120, 144 h post-dose on Day 5

Treatment Period 1: Area Under Plasma Concentration Versus Time Curve from Time Zero to Infinity [AUC(0-inf)] for GSK3923868

Timeframe: Pre-dose, 5, 15, 30, 45 min, and 1, 2, 4, 6, 8, 12, 16, 24, 48 h post-dose

Treatment Period 2: AUC(0-inf) for GSK3923868

Timeframe: Pre-dose, 5, 15, 30, 45 min, and 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96, 120, 144 h post-dose on Day 5

Treatment Period 1: Maximum Observed Plasma Concentration (Cmax) for GSK3923868

Timeframe: Pre-dose, 5, 15, 30, 45 min, and 1, 2, 4, 6, 8, 12, 16, 24, 48 h post-dose

Treatment Period 2: Cmax for GSK3923868

Timeframe: Pre-dose, 5, 15, 30, 45 min, and 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96, 120, 144 h post-dose on Day 5

Treatment Period 1: Time to Reach Cmax (Tmax) for GSK3923868

Timeframe: Pre-dose, 5, 15, 30, 45 min, and 1, 2, 4, 6, 8, 12, 16, 24, 48 h post-dose

Treatment Period 2: Tmax for GSK3923868

Timeframe: Pre-dose, 5, 15, 30, 45 min, and 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, 96, 120, 144 h post-dose on Day 5

Secondary outcomes:

Treatment Period 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Timeframe: Up to Day 9

Treatment Period 2: Number of Participants With AEs and SAEs

Timeframe: Up to Day 24

Treatment Period 1: Number of Participants With Clinically Significant Changes in Hematology and Clinical Chemistry Laboratory Parameters

Timeframe: Up to Day 9

Treatment Period 2: Number of Participants With Clinically Significant Changes in Hematology and Clinical Chemistry Laboratory Parameters

Timeframe: Up to Day 24

Treatment Period 1: Number of Participants With Clinically Significant Changes in Vital Signs

Timeframe: Up to Day 9

Treatment Period 2: Number of Participants With Clinically Significant Changes in Vital Signs

Timeframe: Up to Day 24

Treatment Period 1: Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG) Findings

Timeframe: Up to Day 9

Treatment Period 2: Number of Participants With Clinically Significant Changes in 12-lead ECG Findings

Timeframe: Up to Day 24

Treatment Period 2: AUC(0-t) for Itraconazole and Hydroxy-itraconazole

Timeframe: Pre-dose, 30 min and 1, 1.5, 2, 3, 4, 6, 8, 12 h post-dose on Day 1; and pre-dose, 30 min and 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose on Day 5

Treatment Period 2: AUC(0-inf) for Itraconazole and Hydroxy-itraconazole

Timeframe: Pre-dose, 30 min and 1, 1.5, 2, 3, 4, 6, 8, 12 h post-dose on Day 1; and pre-dose, 30 min and 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose on Day 5

Treatment Period 2: Cmax for Itraconazole and Hydroxy-itraconazole

Timeframe: Pre-dose, 30 min and 1, 1.5, 2, 3, 4, 6, 8, 12 h post-dose on Day 1; and pre-dose, 30 min and 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose on Day 5

Treatment Period 2: Tmax for Itraconazole and Hydroxy-itraconazole

Timeframe: Pre-dose, 30 min and 1, 1.5, 2, 3, 4, 6, 8, 12 h post-dose on Day 1; and pre-dose, 30 min and 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h post-dose on Day 5

Interventions:
Drug: Itraconazole
Drug: GSK3923868
Enrollment:
20
Primary completion date:
2024-16-12
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Pulmonary Disease, Chronic Obstructive
Product
Not applicable
Collaborators
Not applicable
Study date(s)
September 2024 to December 2024
Type
Interventional
Phase
1

Participation criteria

Sex
Female & Male
Age
18 - 65 Years
Accepts healthy volunteers
Yes
  • Participants who are overtly healthy as determined by medical evaluation based on screening medical history, physical examination, vital signs, electrocardiogram (ECG) assessment, pulmonary function testing and laboratory tests.
  • Body weight at least 50 kilograms (kg) and body-mass index (BMI) within the range 18.5 to 32.0 kilogram per meter squared (kg/m^2) (inclusive).
  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
  • Alanine transaminase (ALT) and aspartate aminotransferase (AST) greater than (>) upper limit of normal (ULN).

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Cambridge, United Kingdom, CB2 0GG
Status
Study Complete

Study documents

Study report synopsis
Available language(s): English
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English

If you wish to request for full study report, please contact - [email protected]

Results overview

Results posted on ClinicalTrials.gov

Recruitment status
Completed
Actual primary completion date
2024-16-12
Actual study completion date
2024-23-12

Plain language summaries

Summary of results in plain language
Available language(s): English

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website